Jazz Pharmaceuticals
This sponsor has funded 2 studies across 4 countries.
| EU PAS ID | Status | Title | Protocol uploaded | Results uploaded |
|---|---|---|---|---|
| 5592 | Finalised | A multi-centre, multinational, prospective observational registry to collect safety and outcome data in patients diagnosed with severe hepatic... | Yes | No |
| 29649 | Planned | A National, Post-Registration, Observational Study of the Longterm Safety and Health Outcome of Patients Treated With Defitelio®, Including Patients... | Yes | No |
PAS by Risk Management Plan (RMP) requirement
Jazz Pharmaceuticals
The RMP for a medical product outlines strategies to identify, assess, and mitigate risks, including PAS for further evaluation.
Category 1 studies are imposed as condition of marketing authorisation.
Category 2 studies are imposed as specific obligation of marketing authorisation.
Category 3 studies are required under other circumstances.
PAS by study status
Jazz Pharmaceuticals
The study status is defined according to the timeline dates specified.
Planned studies have not collected any data yet.
Ongoing studies collect data and should publish protocols as soon as possible.
Finalised studies should publish results in the first two weeks after finalisation.
Countries
Jazz Pharmaceuticals
4 Study countries specified are the following:
- France
- Italy
- Portugal
- United Kingdom